Cystitis is a recurring infection in many women of any age and very annoying. In Spain there are vaccines against urinary tract infection and cystitis (UTI) for a long time.
“There are many very different ones developed by different industries, but the vaccine that has caused a global impact is MV140,” he says. Maria Fernanda Lawrencemember of the AEU Group of Functional, Female and Urodynamic Urology.
It’s about a sublingual preparation of four 25% bacteria, which “has shown very potent efficacy in a first-rate scientific study,” he notes. This doctor does not understand how it has not yet been authorized in our country –in other countries of North and South America yes– after the research carried out between Spain and UK confirm the efficacy of this vaccine in a phase III, double-blind, placebo-controlled trial of 240 women.
This clinical trial “has made our country in leader of the sector and has achieved First prizes from the highest international organizations infection experts, such as International Continence Society (ICS) wave Iberoamerican Society of Neurourology and Urogynecology (Sinug)», reveals.
1 in two women
Lorenzo is lead author of this study -“MV140 Sublingual Vaccine Prevents Recurrent Urinary Tract Infections in Women”. “This first-level scientific research with MV140 –he points out– has a first-rate impact because 1 in two women will have a urinary tract infection and cystitis (UTI) throughout their lives and 25% will having recurrent infections (defined as three or more episodes in 1 year or two or more infections in 6 months.” He adds that the vaccine is also effective in males.
Vaccines against cystitis have been prescribed in our country since 2009. «Although they have existed since 1988, the first ones, manufactured in Switzerland, were not authorized in Spain, among other things, because they had many side effects. Currently, the Spanish Agency for Medicines and Health Products (Aemps) only authorizes the use of self-vaccinations,” says Lorenzo.
The self vaccinations They are made from the patient’s own urine. “This is in contradiction with the concept of innate immunity, which does not distinguish the specific microorganism,” he says. In addition, “In the research that I have conducted – adds this specialist – we have shown that MV140 would be very cheap while autovaccines are very expensive.” These are not prescribed as much as they should “because the process until they are obtained is long, they have to go through medical inspection and their preparation takes time. The consequence is that it is used antibiotic treatmentwhich in the long run are worse for people’s health,” he asserts.
Candida albicans
In november the magazine Frontiers in Immunology published an experimental study on the effect of Candida albicans (V132) on the induction of trained immunity in the presence of MV140. The research has been carried out between the Complutense (Madrid, Spain) and Radboud (Nijmegen, Netherlands) universities with the collaboration of Immunotek, developer of this vaccine.
The vaginal yeast infection It appears frequently associated with recurrent urinary tract infections due to continued treatment with antibiotics. In this study, the effects of a combined formulation of MV140 with Candida albicans (V132) have been investigated. It indicates that V132 is a strong inducer of trained immunity with the ability to potentiate the response to MV140.
Discussion about this post